Immuneel Therapeutics bags promising start up award at Endpoints News Awards in Boston, USA
Immuneel is the first startup from India to receive this award
At the Endpoints News Awards in Boston, USA, Immuneel Therapeutics, India’s leading clinical-stage cell and gene therapy startup, was named and awarded amongst ‘Endpoint-11 Biopharma’s Most Promising Startups 2023’.
The event annually honours the top 11 global biopharma startups after rigorous peer review research. This esteemed award not only underscores Immuneel’s significant contributions towards transforming cancer care with innovative and affordable treatments but also positions the company as a global advocate for equitable access. Immuneel is the first startup from India to receive this award.
Kiran Mazumdar Shaw, Co-Founder & Director, Immuneel Therapeutics, said, “We are delighted and proud to be recognised in this super-select club of 11 most ambitious start-ups on the global biotech stage. It was our vision as co-founders of Immuneel, to place India on the CAR-T map, and this acknowledgement goes a long way in affirming our focus to bring affordable transformative cell therapies to India and the world.”
Immuneel aims to disrupt the landscape of cancer treatment in India and beyond and make cell therapies accessible to patients while maintaining global standards. Speaking on this global recognition, Dr Arun Anand, Director & Chief Operating Officer, Immuneel Therapeutics reacted, “This award is a breakthrough moment for Immuneel as well as for India’s biopharma industry. This recognition comes at a time when the biotech industry in India is transforming to be a global force and Immuneel is playing a pivotal role in reshaping the paradigms of cancer treatment through innovation. We extend our gratitude to Endpoints News for this honour.”
Dr Siddhartha Mukherjee, Co-founder & Director, Immuneel Therapeutics, added, “Treatment with CAR-T therapies costs upwards of a million dollars in the US. Through Immuneel’s efforts, we are committed to seeing that patients in India have access to global quality CAR-T treatment at a fraction of this cost.”
Dr Kush Parmar, Co-founder, Immuneel Therapeutics, expressed his gratitude and said, “As we advance in our mission to provide transformative therapies to patients in India and beyond, this award positions us as one of the top 11 startups and the only one looking to create a meaningful impact to cancer patients in regions without access to CAR-Ts. Receiving this award is a matter of pride and joy, it acknowledges the hard work put in by everyone at Immuneel to have traversed the journey from inception to clinical data in just four years.”
